Transgenic mice, which selectively express the WAP-HBX transgene in mammary gland epithelial cells (ME-cells), were established in order to elucidate the consequences of HBX gene expression on organ differentiation, cell death program and tumor development. Transgene expression was demonstrable by RT-PCR, Northern and Western blot analysis during pregnancy, lactation and after weaning. HBX synthesis neither affect mammary gland differentiation nor apoptosis in ME-cells. Although breast cancer formation was rare in WAP-HBX animals (o1%), WAP-HBXp53 þ /À hybrid animals developed breast tumors at an increased rate (12/85) after a latency period of 8-18 months. We also show here for the first time that HBX can immortalize ME-cells generated from mammary gland tissue segments in a p53-independent fashion. HBX causes cyclin D1 gene overexpression during early pregnancy, and this is maintained in ME-cells isolated either from mammary gland or from breast tumors. Intranuclear cyclin D1 accumulation also occurs in the absence of external growth factors and the BrdU incorporation rate remains high under serum starvation conditions. Finally, both cyclin D1 induction and HBX mitotic activity are dependent on p38 and c-Jun N-terminal kinase, but not on MEK-1 kinase activity.
Introduction
Human hepatocellular carcinoma (HCC) is highly prevalent and its promotion by HBX is strongly supported by both epidemiological and experimental studies (Beasley et al., 1981; Ganem and Varmus, 1987) . HBX is a multifunctional protein. It modulates the sensitivity of cells to cytokines and growth factors, transactivates multiple cellular and viral genes, and forms complexes with different cellular proteins, such as the p53 tumor suppressor protein. In addition, it alters the cell death program. However, in spite of extensive studies undertaken during the last decades, it remains unclear how HBX promotes malignant cell transformation (reviewed in Murakami, 1999; Arbuthnot et al., 2000; Diao et al., 2001) .
To better understand HBX functions, we generated transgenic animals (WAP-HBX animals), which selectively express the HBX gene in the mammary gland epithelial cells (ME-cells). Although ME-cells are not the natural target for hepatitis B virus (HBV), the mammary gland is well suited for the study of cell differentiation, the apoptotic pathway and cancer formation. During each pregnancy, this organ undergoes an extensive process of differentiation and involution. Adipose cells are replaced by the ME-cells, which form the well-defined lobulo-alveolar structure responsible for milk production and secretion during lactation. Organ differentiation and activation of the milk protein genes (e.g. WAP) require the coordinative action of various lactogenic hormones (e.g. estrogen, progesterone, prolactin, insulin, hydrocortisone) and different tissue factors. After weaning the majority of ME-cells, which account for up to 25% of the animal body weight, are eliminated by apoptosis within a few days (Tzeng et al., 1998) .
It is well documented that various oncogenes are able to hinder mammary gland differentiation, to deregulate the cell death program and to induce breast cancer formation (Jehn et al., 1992; Siegel et al., 2000) . In the case of SV40, the large T-antigen causes premature mammary gland involution during late pregnancy and as a consequence of the pronounced apoptotic rate, WAP-SV40 T/t animals are unable to feed their litters and show a high frequency of breast cancer (Tzeng et al., 1993; Santarelli et al., 1996) . In the mammary gland of transgenic animals which synthesize only the small tantigen (WAP-SV40t) cyclin D1 expression is upregulated causing early ME-cell proliferation. However, the cells do not respond to differentiation signals and development of the regular lobulo-alveolar network of the mammary gland is inhibited. These animals show low levels of breast cancer (Goetz et al., 2001) . In this investigation, we demonstrate that WAP-HBX transgenic animals synthesize HBX in the ME-cells.
However, HBX alters neither the mammary gland differentiation program nor the feeding capability of the animals, but causes a strong upregulation of cyclin D1. Furthermore, HBX has no proapoptotic activity during either the mammary gland development (pregnancy, lactation) or in the ME-cells of established tissue culture cell lines. WAP-HBX animals develop breast cancer at a low efficiency (o1%). However, the tumor rate is significantly increased in WAP-HBXp53 þ /À and WAP-HBXp53À/À hybrid transgenic animals. A low p53 level per se is insufficient to induce breast cancer formation, as neither p53 þ /À nor p53À/À animals develop breast tumors.
Results and discussion

HBX does not affect mammary gland differentiation
In order to direct HBX gene expression selectively in mammary gland epithelial cells, the WAP-HBX gene was microinjected into fertilized mouse eggs (strain NMRI) and two independent transgenic mice lines were established (WAP-HBX1 and WAP-HBX2). Females from these two lines have similar properties and express the WAP-HBX transgene synchronously with the endogenous WAP gene during pregnancy and lactation. This was shown by RT-PCR (Figure 1 ), Northern blot ( Figure 2a ) and Western blot analysis (Figure 2b ). Furthermore, WAP as well as WAP-HBX gene expression continues in ME-cells which remain in the mammary glands after involution (Figure 1, postlactation) .
To test whether HBX affects mammary gland differentiation, small gland tissue segments were isolated during pregnancy (days 12, 16, 18), lactation (days 1, 3, 10) and after weaning (days 1, 5, 15) of monoor multiparous animals. Thin sections of these segments were then subjected to histological examination. Furthermore, three kinds of control animals were investigated, namely nontransgenic NMRI mice, WAP-SVT and WAP-SVt transgenic animals, which selectively synthesize either the SV40 large T-antigen or the SV40 small t-antigen in ME-cells (Goetz et al., 2001) . These experiments revealed that the WAP-HBX transgenic animals develop a well-defined lobulo-alveolar morphology with single layers of epithelial cells as seen in the NMRI control mice during pregnancy and early lactation ( Figure 3A, a, b) . Furthermore, WAP-HBX animals show a normal feeding capability and mammary gland involution occurs after weaning as in the NMRI animals. Approximately 80-90% of ME-cells are eliminated by apoptosis within 4-5 days (data not shown). Therefore, HBX has no significant effect on mammary gland differentiation or the gland involution program (Figure 3A, b) . This is in contrast to the SV40 T-antigen, which induces premature mammary gland involution during late pregnancy by increased apoptosis ( Figure 3A , c). The SV40 t-antigen inhibits mammary gland differentiation during early pregnancy (Goetz et al., 2001) . However, as in the case of the HBX, it does not increase the rate of ME-cell death (data not shown). Thus, WAP-SVT and WAP-SVt transgenic animals are not able to nurse their progeny, while WAP-HBX animals have a normal feeding capability.
HBX does not affect apoptotic activity in mammary gland epithelial cells
Although the above experiments strongly support the assumption that HBX does not increase the ME-cell Figure 1 RT-PCR analysis: Mammary gland tissue segments were isolated from normal (NMRI) and WAP-HBX transgenic animals during pregnancy (day 19), lactation (day 1) and postlactation (5 weeks). RNA was extracted from these tissue segments, converted into cDNA and PCR amplified. Cell cycle numbers and the size of the expected PCR products for WAP, HBX, cyclin D1 and GAPDH are indicated. WAP-HBXp53 þ /À and WAP-HBXp53À/À animals exhibited a similar HBX expression level as the WAP-HBX transgenic animals, data not shown apoptosis rate (a 2-3% daily increased cell death rate during the lactation period of 20 days would prevent lactation), we further stained mammary gland tissue sections with Hoechst staining solution ( Figure 3A ). This confirmed that HBX does not increase the ME-cell death rate during pregnancy and lactation. Furthermore, DNA fragmentation, a hallmark of ME-cell apoptosis (Tzeng et al., 1998) , could not be shown by TUNEL analysis (data not shown) or agarose gel electrophoresis, but was pronounced in the mammary glands of control WAP-SVT transgenic animals ( Figure 3B ). Taken together, these experiments demonstrate that HBX, as the SV40 t-antigen, does not exert a spontaneous proapoptotic effect on ME-cells in monoor multiparous animals. These findings are comparable to results obtained with ATX mice, where HBX did not induce apoptosis in liver cells (Madden et al., 2000) . However, related studies suggest that HBX triggers an apoptotic process in hepatocytes of transgenic animals ). An augmented apoptotic rate was also observed in p53À/À transgenic animals implying that in hepatoma cells HBX-mediated cell death is p53 independent . We also generated WAP-HBXp53À/À double transgenic animals (see below), but ME-cell apoptosis could not be demonstrated. Opposing data have been reported for cultured cells where HBX exerted a proapoptotic activity (Chirillo et al., 1997; Su and Schneider, 1997; Kim et al., 1998; Terradillos et al., 2002) or protected cells against various cell death stimuli, such as TNFa, serum starvation and doxorubicin (Wang et al., 1995; Gottlob et al., 1998b) . Currently, no proposal has been put forward to explain why under certain conditions, HBX either induces or prevents cell death. However, it should be noted that the N-terminal amino-acid sequence of HBX may determine the pro-or antiapoptotic response. Functional mapping experiments have revealed that the amino acids 1-50 of the HBX are dispensable for antiapoptotic activity but essential for proliferative function (Gottlob et al., 1998b) . Furthermore, it has been shown that the accumulation of mutations in the 5 0 region of the HBX gene abrogates Overexpression and development of breast cancer in transgenic animals A Klein et al both the apoptotic and antiproliferative effects of the viral protein (Sirma et al., 1999) .
HBX induces a low frequency of breast cancer
To test whether HBX leads to breast tumors, more than 100 multiparous (two to four pregnancies) WAP-HBX animals were monitored over a period of 18-20 months.
Only one female animal developed breast cancer (Table 1) . This low tumor rate is in accordance with the concept that HBX is a very weak oncoprotein. Transgenic animals synthesizing the HBX in liver cells do not always exhibit an increased rate of liver cancer, although these animals are more susceptible to carcinogens or activated oncogenes (Dragani et al., 1990; Slagel et al., 1996; Terradillos et al., 1997) . At present, it is not clear how HBX promotes HCC formation. It is well documented that HBX is a multifunctional protein that transactivates several cellular genes and cooperates with many cellular proteins including the p53 tumor suppressor protein (reviewed in Arbuthnot et al., 2000) . In vitro and in vivo experiments suggest that HBX sequesters p53 in the cytoplasm causing a functional depletion of p53. This HBX function has been linked directly with the development of liver cancer (Ueda et al., 1995) .
In order to verify whether a reduced level of p53, combined with HBX synthesis increases the risk of breast cancer, the WAP-HBXl animals were crossed with p53À/À and 85 multiparous WAP-HBXl p53 þ /À females were followed over an 18-20 month period. All WAP-HBX1p53 þ /À animals exhibited normal mammary gland development and a normal feeding pattern. However, as summarized in Table 1 , about 14% (12/85) of the hybrid animals developed breast cancer. Tumor formation occurred mostly in the inguinal glands ( Figure 4a ) with latencies ranging from 8 to 18 months ( Figure 4b ). Tumor growth was progressive after onset and the tumors had to be eradicated 3-4 weeks later. WAP and WAP-HBX transgene expression could be shown in all breast tumors by RT-PCR analysis (e.g. HBX-tumor 1, Figure 5 ). Importantly, none of the control NMRIp53 þ /À hybrid animals developed breast cancer (0/49). DNA sequencing experiments confirmed that p53 mutations were not associated with tumor formation in the WAP-HBX1p53 þ /À animals. It is still uncertain whether the entire functional loss of p53 further increases the breast tumor rate, since we obtained only 11 WAP-HBXlp53À/À double transgenic females and these animals died within the ages of 4-9 month because of a high spontaneous tumor rate (e.g. lymphomas). Nevertheless, two of the WAPHB1X1p53À/À animals developed breast tumors (Table 1) .
These observations imply that lower levels of functional p53 molecules in the ME-cells per se are not the reason for the increased breast tumor rate in the WAPHBX1p53 þ /À animals. If this were the case, the NMRIp53 þ /À or p53À/À mice would develop breast cancer at a higher rate than control NMRI animals. However, neither p53 þ /À nor p53À/À animals developed breast cancer (Table 1) . Therefore, it is feasible that HBX synthesis associated with a lower p53 level increases the risk for malignant ME-cell transformation. In contrast to results reported elsewhere (Feitelson et al., 1993; Elmore et al., 1997) , we could not demonstrate complex formation between HBX and p53, nor cytoplasmic retention of p53 in ME-cells transiently overexpressing the CMV-HBX transgene (data not shown) or in HBX-positive rat fibroblast (REV2) cells (Gottlob et al., 1998a) .
Thus, the cytoplasmic retention of p53 by HBX is not always essential for a higher cancer risk. Furthermore, related studies demonstrated that truncated HBX molecules, lacking the p53-binding region, still transform tissue culture cells (Kumar et al., 1996; Gottlob et al., 1998a) .
In this respect, it is relevant that several groups have reported a direct role of HBX on DNA repair in a p53-independent fashion (Lee et al., 1995; Becker et al., 1998) implicating that HBX activity in combination with lower p53 levels might increase the tumor risk of the WAP-HBX1p53 þ /À animals.
However, it should be noted that in our WAPHBX1p53 þ /À transgenic animals, the malignant MEcell transformation is not associated with any HBX mutation. Such mutations have been shown elsewhere (Sirma et al., 1999; Huo et al., 2001) .
HBX immortalizes ME-cells
Mouse ME-cells from normal and p53À/À animals have a very limited lifespan in vitro and it has not been possible to establish stable cell lines under standard tissue culture conditions (Dulbecco's modified Eagle's medium, DMEM, 10% fetal calf serum, FCS) to date (Tzeng et al., 1998) . However, we demonstrate here that Breast tumor ME-cell apoptosis ME-cell immortalization
Overexpression and development of breast cancer in transgenic animals A Klein et al HBX has the capability to immortalize ME-cells. For this purpose, tissue segments, were isolated from the mammary glands of transgenic animals (WAP-HBX1; WAP-HBX1p53 þ /À; WAP-HBX1p53À/À) during the first pregnancy and lactation, plated in culture dishes and further propagated under standard tissue culture conditions. From these tissue segments, HBX-ME-cells could be grown out and formed confluent monolayers within 2-3 weeks. At passage numbers 2-4, the HBX-ME-cells entered crisis, but about 3-5% of these cells survived and stable lines could be established without clonal selection. Cells from all of these lines have the morphology and growth characteristic of nonmalignant cells (data not shown). This further demonstrates that HBX synthesis per se does not cause malignant ME-cell transformation. In addition, the fact that the HBXp53À/À ME-cells do not undergo malignant transformation indicates that p53 is not the most critical HBX downstream target for this progression in ME-cells. We further established nine permanent ME-cell lines (HBX-ME/1-9-cells) from the breast tumors of nine independent WAP-HBX1p53 þ /À animals and two from WAP-HBX1p53À/À animals. In contrast to the ME-cell lines described above (WAP-HBX1; WAPHBX1p53 þ /À; WAP-HBX1p53À/À), ME-cell lines generated from the breast tumor sections remained malignant transformed in tissue culture. As exemplarily shown for the HBX-MEl/cells (source: HBX breast tumor 1), these tumor cell lines are small epithelial cells that are not contact inhibited and exhibit anchorageindependent growth characteristic of malignant transformed cells (Figure 6a, b) . The HBX-ME/1-cells are at a high passage number (480), but WAP and WAP-HBX transgene expression are still demonstrable by RT-PCR analysis ( Figure 5) . However, the HBX-MEcells of three lines (e.g. HBX-ME/5-cells) switched off both WAP as well as WAP-HBX gene expression during early passages (data not shown). Although the HBX-ME/5-cells become HBX negative, these cells still exhibit the morphology and growth characteristic of breast tumor cells. This is in contrast to the SV40 T-antigen ME-tumor cells (T-ME-cells). These T-ME-cells, which switched off the WAP-SVT transgene in tissue culture, acquired the morphology and growth characteristic of nontransformed ME-cells, unless the cells carried a p53 missense mutation (e.g. codon 242; Tzeng et al., 1998) . This indicates that malignant ME-cell transformation, mediated by HBX, is a hit and run event. Therefore, HBX may predispose ME-cells to additional not yet identified hits, which then makes HBX synthesis dispensable for maintenance of the transformed state.
HBX causes overexpression of cyclin D1 in ME-cells
Cyclin D1 is a member of the G1 phase cyclin family (cyclin D and E). Cyclin D1 gene expression is induced by extra-or intracellular mitotic signals, reaching a maximal level at the mid-G1 phase of the cell cycle. It forms a functional protein kinase complex with either CDK4 or CDK6. Hyperphosphorylation of pRb through the cyclin D1/CDK4 complex causes activation of the E2F transcription factor and leads to cyclin E gene expression. Overexpression of G1 phase cyclins is a Immunohistological experiments revealed that the G1 cyclines are upregulated in established HBX-positive ME-cell lines. When stained with cyclin D1 antibodies, the majority of the cells exhibit a strong intranuclear cyclin D1 fluorescence in a cell-cycle-independent fashion (Figure 6c) . Furthermore, overexpression of cyclin D1 is serum independent. When the cells were cultivated up to 96 h in serum-free (0%) DMEM medium, cyclin D1 remained upregulated, demonstrable either by immunofluorescence staining (data not shown) or by Western blot analysis (e.g. HBX-ME/1-cells; Figure 7a ). Comparable results were obtained when ME-cells were stained with cyclin E antibodies (data not shown). Additionally, HBX-ME-cells of all established lines incorporated 5-bromo-2 0 -deoxy-uridine (BrdU) after serum starvation with a similar efficiency as control HBX-ME-cells cultivated under standard conditions (DMEM, 10% FCS). Deregulation of the G1 phase cyclins is not restricted to cells of the breast HBX-ME/1-cell histology and immunofluorescence staining: (a) phase contrast picture; (b) growth in soft agar; (c) cells were cultivated for 18 h in DMEM without serum in the presence of the MEK1 inhibitor PD 98059 and stained with cyclin D1 antibody and (d) stained with anti BrdU antibody; in control experiments similar results were obtained when the HBX-ME/1-cells were cultivated in the absence of the MEK1 inhibitor (data not shown); (e) cells were cultivated in DMEM with 10% serum in the presence of the p38 inhibitor SB 202190 and cyclin D1 stained; (f) the same cells stained for BrdU; (g) cells were cultivated in DMEM with 10% serum in the presence of the N-JNK inhibitor dicumarol and stained for cyclin D1; (h) the same cells stained for BrdU. (i) T-ME-cells cultivated in DMEM with 10% serum and stained for cyclin D1; (j) T-ME-cells cultivated for 18 h in DMEM with 10% serum in the presence of dicumarol and stained with BrdU antibody. Original magnification Â 250
Overexpression and development of breast cancer in transgenic animals A Klein et al tumors or to the corresponding established tumor HBX-ME cell lines ( Figure 5 ). RT-PCR analysis (Figure 1) and Western blot studies (data not shown) revealed that cyclin D1 upregulation already occurs in the mammary glands during the first pregnancy period and it continues in the ME-cells during lactation and after weaning (Figure 1 ) of all transgenic animals analysed (WAP-HBX1, WAP-HBX1p53 þ /À, WAP-HBX1p53À/À). The high cyclin D1 level is further maintained in the ME-cells of established lines generated from these above-mentioned mammary glands. This indicates that upregulation of the G1 cyclins is not sufficient to cause malignant ME-cell transformation, because ME-cells of these lines exhibit the morphology and growth characteristic of normal epithelial cells.
Since overexpression of cyclin D1 in cancer cells is frequently associated with gene amplification (Brison, 1993; Bieche and Lidereau, 1995) , genomic DNA was isolated from the HBX-ME/1-cells and subjected to Southern blot analysis and DNA sequencing. Cyclin D1 gene amplification or mutations within the promoter region were not demonstrable (data not shown). Taken together, our experiments indicate that HBX induces constitutive overexpression of the G1 cyclins, independent of extracellular mitotic signals.
It is well established that HBX activates the Ras-Raf mitogen-activated protein (MAP) kinase (ERK) and the stress induced c-Jun N-terminal kinase (N-JNK) pathway (Benn and Schneider, 1994; Natoli et al., 1994; Su et al., 2001) .
To prove whether overexpression of cyclin D1 is RasRaf-dependent, monoclonal c-Ras and/or c-Raf antibodies were microinjected into the cytoplasm of HBX-ME/1-cells. Immunofluorescence staining experiments revealed that neither cyclin D1 synthesis nor BrdU incorporation was affected by the injected antibodies (data not shown). To obtain further information about the involvement of potential downstream effectors, different MAP kinase inhibitors, such as PD 98059 (MEKl inhibitor), dicumarol (N-JNK inhibitor) or SB 202190 (p38 inhibitor) were added to the culture medium of the HBX-ME/1-cells. After an incubation period of 18 h, cyclin D1 expression level was determined by immunofluorescence staining and by Western blot analysis. As shown in Figure 6e and g, application of SB 202190 (25 mm) and dicumarol (140 mm), respectively, caused a strong reduction of the intranuclear cyclin D1 level and inhibited BrdU incorporation (Figure 6f and h). Western blot analysis revealed that the inhibitory effect of dicumarol was stronger (Figure 7d ) than the effect of SB 202190 and was more pronounced when the HBX-ME/1-cells were maintained under serum-free conditions for 18 h (Figure 7c ). In contrast, the MEK1 inhibitor PD 98059 (50 mm) gave no detectable decrease of the cyclin D1 level (Figure 6c ) nor a reduction of the BrdU incorporation rate, when added to the culture medium either with or without serum (Figure 6d ). Similar results were obtained when protein extracts were subjected to Western blot analysis (Figure 7b) .
The SV40 t-antigen also causes cyclin D1 upregulation in a growth factor-independent fashion in t-MEcells, as reported elsewhere (Goetz et al., 2001) . To test whether cyclin D1 upregulation in these cells is also mediated by the stress-related MAP kinases, the inhibition experiments described above were repeated with the t-ME-cells. These studies revealed that SV40 tantigen-induced cyclin D1 overexpression and BrdU incorporation are both inhibited by dicumarol and to a lower extent by SB 202190 but not by PD 98095 (Figure 7e) , as in the case of the HBX (Figure 7b-d) .
In contrast to the HBX and SV40 t-antigen, the SV40 T-antigen does not induce the cyclin D1 overexpression in ME-cells (e.g. T-ME-cells, Figure 6i ) and a strong decline of the cyclin D1 level occurred under serum starvation conditions (Figure 7f ). However, none of the kinase inhibitors (PD 98095, SB 202190, dicumarol) caused a significant reduction of the cyclin D1 level (data not shown) nor inhibited BrdU incorporation into the DNA of the T-ME-cells, when either cultivated with or without serum (e.g. dicumarol, Figure 6j ). Nevertheless, following transfection of the CMV-HBX DNA into T-ME-cells (T/HBX-ME-cells), cyclin D1 overexpression occurred as in the HBX-ME/1-cells (data not shown), confirming that deregulation of the G1 cyclins in the ME-cells is a specific function of the HBX protein.
At present, it is not clear how these viral proteins induce cellular DNA replication. However, in the case of the SV40 T-antigen, induction of DNA synthesis is independent of cyclin D1 overexpression and MEK1-, N-JNK-or p38 kinase activities. On the contrary, the mitotic effect exerted by HBX and SV40 t-antigen requires the synergistic activation of p38 and N-JNK, since both kinase inhibitors (SB 202190, dicumarol) blocked cyclin D1 upregulation and ME-cell division, which indicates that these two viral proteins may act as cytoplasmic stress signals.
In this investigation we have directed HBX synthesis in the mammary gland epithelial cells of transgenic animals via the WAP promoter. Although the ME-cells are not the natural target of HBV, certain conclusions can be drawn from this study that also could be of relevance for HBX-related pathology:
(i) HBX synthesis per se is not cell toxic and in contrast to the SV40 T/t-antigens does not affect the organ differentiation program of the mammary gland. This observation is somewhat unexpected, considering the fact that HBX is a multifunctional protein, which interacts with many proteins that are key players in gene expression and for cell differentiation (reviewed in Murakami, 1999; Arbuthnot et al., 2000; Diao et al., 2001) .
(ii) The results obtained with the WAP-HBX transgenic animals confirm that HBX acts as a weak tumor promoter protein and that under certain circumstances it mediates malignant cell transformation and tumor formation, although the oncogenic mechanisms still remain unclear. Moreover, the data obtained with the WAP-HBXlp53 þ /À animals reveal that the p53 level of the ME-cells combined with HBX synthesis increases the risk for tumor formation.
(iii) A further HBX target, frequently associated with tumorigenesis, is the cyclin D1 gene, which is upregulated in the ME-cells of WAP-HBX transgenic animals (WAP-HBX, WAP-HBXlp53 þ /À, WAPHBXlp53À/À). However, overexpression of cyclin D1 per se is not sufficient for tumor formation, bearing in mind that high levels of cyclin D1 already occur early in the first pregnancy and that breast cancer formation in the WAP-HBX transgenic animals is a very rare event.
(iv) Finally, it is demonstrated in this investigation, that HBX has the potential to immortalize ME-cells, a feature which may be a further critical factor for tumor formation.
Materials and methods
Plasmid constructs and generation of transgenic mice
The WAP-HBX construct contains the 1600 bp BgIII-KpnI promoter segment of the murine WAP gene (whey acidic protein) with its upstream regulatory sequences (Tzeng et al., 1993) , followed by the HBV nucleotides 1372-1833, corresponding to the HBV-X coding region and the nucleotide sequence encoding the FLAG polypeptide (DYKDDDDF) (Gottlob et al., 1998a) . The HBX sequence used in this investigation belongs to the ayw subtype group. Two copies of the linear WAP-HBX gene were microinjected into fertilized mouse eggs (NMRI) as described earlier (Tzeng et al., 1993) and two independent transgenic mice lines were generated (WAP-HBX1 and WAP-HBX2). Furthermore, WAP-HBX1 animals were crossed with p53À/À animals (Donehower et al., 1992) and a WAP-HBXlp53 þ /À mouse line was established. Construction of the WAP-SVt and WAP-SVT animals has been described elsewhere (Goetz et al., 2001) . The accuracy of all constructs was confirmed by DNA sequencing with the Applied Biosystems Model 373 A utilizing dye terminators (Perkin-Elmer).
ME-cell lines
To establish ME-cell tissue culture lines, small tissue segments were isolated from mammary glands during pregnancy, lactation and postlactation from all WAP-HBX animals and from breast tumors originating in WAP-HBXlp53 þ /À, WAP-HBXlp53À/À, WAP-SVt and WAP-SVT animals, transferred into tissue culture dishes and cultivated in DMEM Gibco BRL Life Technologies), supplemented with 10% (FCS, Gibco BRL Life Technologies).
COS 7 cells (Gluzman, 1981) were grown in DMEM with 5% FCS and transfected with the pCMV-X/F plasmid (Gottlob et al., 1998a) using the calcium phosphate method. c-Ras (F235, Santa Cruz Biotechnology) and/or c-Raf antibodies (554134, BD PharMingen) were microinjected into the cytoplasm of HBX-ME/1-cells as described elsewhere (Graessmann and Graessmann, 1983) . The SVT/HBXl-ME-cells were obtained after transfection of the pCMV-X/F plasmid into T-ME-cells and G418 selection.
Histology
Tissue segments were fixed in 10% formaldehyde in phosphate-buffered saline (PBS) and embedded in paraffin. Thin sections (4.5 nm) were stained with hematoxylin/eosin and Hoechst staining solution 33258 (8 mg/ml; Merck).
Immunofluorescence staining
The permanent tumor cell lines (HBX-ME/1-cells, T-ME-cells, t-ME-cells) were grown in DMEM with 10% FCS for 32 h after plating. The cells were then incubated with either 25 mm of the p38 inhibitor SB 202190 (Calbiochem), or 140 mm of the N-JNK inhibitor dicumarol (Sigma) (Krause et al., 2001) , or 50 mm of the MEK1 inhibitor PD 98059 (Calbiochem) in medium with either 10% FCS or without FCS, for 18 h. Cells were washed in PBS, fixed in a methanol/acetone 1 : 2 v/v solution, dried on air and incubated either with monoclonal cyclin Dl antibody (72-13G, Santa Cruz Biotechnology) or polyclonal cyclin E antibody (#06-459, Upstate Biotechnology) at 371C for 30 min. Either rhodamine sheep anti-mouse or goat anti-rabbit was used as secondary antibody (515-025-003 and 111-025-045, Jackson ImmunoResearch Laboratories, Inc.). BrdU incorporation was used to visualize DNA synthesis by immunofluorescence staining with the BrdU labeling and detection Kit 1296736 (Roche Applied Science). BrdU was added to the culture medium 4 h before cell fixation. TUNEL (TdT-mediated dUTP nick end labelling) staining was performed according to the manufacture's instructions using the in situ cell death detection kit (1767291, Roche Applied Science).
RNA preparation and Northern blot analysis
RNA was isolated from mammary gland tissue segments from NMRI, WAP-HBX1/2, WAP-HBX1p53 þ /À and WAPHBXlp53À/À transgenic animals, as well as, from WAPHBXlp53 þ /À and WAP-HBXlp53À/À breast cancer segments. RNA was further isolated from different ME-cell cell lines (HBX-ME/1-, T-ME-and t-ME-cells). In short, the RNA was extracted with guanidinium thiocyanate and pelleted through a 5.7 m cesium chloride cushion as described elsewhere (MacDonald et al., 1987) . The polyA RNA was separated from 300 mg total RNA using the polyATtract mRNA isolation system (Promega). For Northern blot analysis, the WAP-RNA (20 mg of total RNA) and HBX-RNA (3 mg of polyA RNA) were separated on agarose gels under denaturing conditions (1.2% agarose, Sigma; 0.66 m formaldehyde, Merck), transferred to a nylon membrane (Hybond-N, Amersham) and hybridized with either a DIG-labeled 284 bp WAP cDNA segment or with a DIG-labeled 500 bp HBXantisense RNA segment. The blots were developed using the DIG luminescence detection kit (Roche Applied Science).
RT-PCR analysis
Total RNA (5 mg) was reverse transcribed into cDNA with 200 U of superscript RT (Gibco Life Technologies) and 25 ng pd(N) 6 random primers (Amersham Pharmacia Biotech) in a final volume of 20 ml enzyme buffer (Gibco BRL Life Technologies) for 60 min at 421C. PCR was performed with 100 ng of cDNA in a 50 ml reaction solution, containing 20 mm Tris, pH 8.0, 50 mm KC1, 2 mm MgCl 2 , 10 mm of each dUTP, 20 pmol of each primer and 1.25 U of Taq DNA polymerase (Gibco). The cycling profile was 941C for 45 s, 501C (between 50 and 661C) for 45 s and 721C for 1 min for the indicated cycles and a final extension at 721C for 7 min. The PCR products were separated on 1.5% agarose gels and visualized by ethidium bromide staining.
The primer sets used for the semiquantitative PCR were: for HBX: 5 0 -GGCTGTGCTGCCAACTGGA-3 0 and 5 0 -GGTG-AAAAAGTTGCATGGTGCTGG-3 0 ; for WAP: 5 0 -AGTCC-ATGTTCCAAAAAG-3 0 and 5 0 -TGTACATG-TCATGACA-CA-3 0 ; for SV40 T/t-antigen: 5 0 -GCTTTGCAAAGATGGA-TAAAG-3 0 and 5 0 -ACTAAACACAGC ATGACTC-3 0 ; for cyclinD1: 5 0 -GTGCC-ATCCATGCGGAA-3 0 and 5 0 -GGAT-GGTCTGCTTGTTCTCA-3 0 ; for GAPDH: 5 0 -CCCCTTCA-TTGACCTCAACTAC-3 0 and 5 0 -TTGAAGTCGCAGGAG-ACAACC-3 0 .
DNA isolation
Genomic DNA was isolated from tissue segments of WAPHBX1p53 þ /À animals for Southern blot analysis as described elsewhere (Sambrook et al., 1989) . Total DNA was isolated from mammary glands of WAP-HBX1 and WAP-SVT animals for detection of DNA fragmentation at the first day of lactation. In short, the tissue segments were homogenized and digested with proteinase K (1 mg/ml, Roche Applied Science) in 1 ml of digestion buffer at 551C for 20 h. After RNAse treatment and phenol-chloroform extraction, the nucleic acids present in the solution were precipitated with ethanol. DNA (5-10 mg) was subjected to agarose gel electrophoresis (1.5% agarose gel; 60 mA; running buffer: Tris-HCl 40 mm, Na acetate 5 mm, EDTA 1 mm, pH 7.9). DNA fragmentation was visualized by ethidium bromide staining.
Immunoprecipitation and Western blot analysis
The permanent cell lines (HBX-ME/1-cells, T-ME-cells, t-ME-cells) were grown in DMEM with 10% FCS for 32 h after plating. The cells were then incubated with either 25 mm of the p38 inhibitor SB 202190 (Calbiochem) or 140 mm of the N-JNK inhibitor dicumarol (Sigma), or 50 mm of the MEK1 inhibitor PD 98059 (Calbiochem) in medium with either 10% FCS or without FCS, for 18 h. Whole-cell extracts were prepared in lysis buffer (50 mm Tris-HCl, pH 7.8, 150 mm NaCl, 2.5 mm EDTA, 1% NP-40, 1 mm PMSF and 10 mg/ml of the protease inhibitors pepstatin, aprotinin and leupeptin). The above-mentioned cells were cultivated 2 days after plating for 48 h with or without 10% FCS for serum starvation experiments. Total protein (50 mg) were separated by electrophoresis in 12% SDS-polyacrylamide gels and transferred onto a PVDF membrane (Carl Roth GmbH Co., Karlsruhe, Germany) with a semidry transfer apparatus (Biometra). The filters were hybridized either with monoclonal mouse cyclin D1 antibody (72-13G, Santa Cruz Biotechnology) or polyclonal rabbit cyclin E antibody (#06-459, Upstate Biotechnology). Blots were then incubated either with anti-mouse-HRP or antirabbit-HRP (PO447 or PO448, Dako, Denmark) and developed using a chemiluminiscence detection system (NEN Life Science Products, Inc., Boston, MA, USA). After stripping in 50 mm Tris-HCL, pH 6.8, 2% sodium dodecyl sulfate, 100 mm 2-mercaptoethanol for 15 min by 551C, the membranes were incubated with monoclonal b-actin antibody (AC-74, Sigma). Cell lysates, for detection of the HBX, were prepared from mammary gland segments of WAP-HBX1 animals and NMRI control mice at the first day of lactation using the following lysis buffer 50 mm Tris-HCl, pH 8.0, 150 mm NaCl, 2.5 mm EDTA, 1% NP-40, 0.25% sodium desoxycholate, 0.1% sodium dodecyl sulfate, 1 mm PMSF and 10 mg/ml of the protease inhibitors pepstatin, aprotinin and leupeptin. To obtain a positive HBX control, 2 mg of protein extract, isolated from COS 7 cells 48 h after transfection with the pCMV-X/F construct, was treated with the mouse monoclonal HBX antibody (MAB8419, Chemicon) and protein A/G (Pierce). The immunoprecipitates were separated on a 12% SDS-polyacrylamide gel, electro blotted onto PVDF membrane (Roth) and probed with 200 ng/ml of the MAB8419 antibody.
